Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216953 | 0.86 | CHRM2 (0.43) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3227028 | 0.79 | PLK4 (0.38) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3201421 | 0.79 | CHRM3 (0.48) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3201433 | 0.79 | SMN1; SMN2 (0.39) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4620492 | 0.79 | CHRM3 (0.43) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4618316 | 0.76 | ALDH1A1 (0.48) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3210004 | 0.76 | CHRM2 (0.41) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4619110 | 0.74 | ALDH1A1 (0.45) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4618035 | 0.74 | ALDH1A1 (0.43) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4618103 | 0.73 | GAA (0.43) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.